PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis

Bone

Volumn 19, Issue 4, 1996, Pages 303-306

  Stewart, Andrew F ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anabolic; Bone; Osteoporosis; PTH related protein

Indexed keywords

PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN[1-36]; PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG;

BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; HORMONE SYNTHESIS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OSTEOPOROSIS; PROTEIN LOCALIZATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030272262     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(96)00221-9     Document Type: Short Survey

References (41)

1. 1. Abugassa, S., Nordenström, J., Eriksson, S., and Sjödén, G. Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 76:1617-1621; 1993.
2. 2. Broadus, A. E. and Stewart, A. F. Parathyroid hormone-related protein: Structure, processing and physiological actions. Bilezikian, J. P., Levine, M. A., and Marcus, R., Eds. The Parathyroids, basic and clinical concepts. New York: Raven; 1994; 259-294.
3. 3. Cauley, J. A., Seeley, D. G., Ensrud, R., Ettinger, B., Black, D., and Cummings, S. R. Estrogen replacement therapy and fractures in older women. Ann Int Med 122:9-16; 1995.
4. 4. Dempster, D. W., Cosman, F., Parisien, M., Shen, V., and Lindsay, R. Anabolic actions of parathyroid hormone on bone. Endocrine Rev 14:690-709; 1993.
5. 5. Ebeling, P. R., Jones, J. D., O'Fallon, W. M., Janes, C. H., and Riggs, B. L. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab 77:1384-1387; 1993.
6. 6. Ejersted, C., Andreassen, T. T., Oxlund, H., Jorgensen, P. H., Bak, B., Haggblad, J., Torring, O., and Nilsson, M. H. L. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 8:1097-1101, 1993.
7. 7. Everhart-Caye, M., Inzucchi, S. E., Guinness-Henry, J., Mitnick, M. A., and Stewart, A. F. Parathyroid hormone-related protein (1-36) is equipotent with parathyroid hormone (1-34) in humans. J Clin Endocrinol Metab 81:199-208; 1996.
8. 8. Finkelstein, J. S., Klibanski, A., Schaefer, E. H., Hornstein, M. K., Schiff, I., and Neer, R. M. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618-1623; 1994.
9. 9. Fraher, L. J., Hodsman, A. B., and Jonas, K. et al. A comparison of the in vivo biological responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab 75:417-423; 1992.
10. 10. Fraher, L. J., Klein, K., Marier, R., and Freeman, D. et al. Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. J Clin Endocrinol Metab 80:60-64; 1995.
11. 11. Fujiyama, K., Kiriyama, T., Ito, M., Nakata, K., Yamashita, S., Yokoyama, N., and Nagataki, S. Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. J Clin Endocrinol Metab 80:2135-2138; 1995.
12. 12. Guinness-Henry, J., Mitnick, M. A., and Stewart, A. F. Subcutaneously injected PTHrP(1-36) is active in humans. 10th International Congress of Endocrinology, Program and Abstracts, June 12-15, 1996. Abstract OR 9-6, p. 60.
13. 13. Henderson, J. E., Amizuka, N., Warshawsky, H., Diasotto, D., Lanske, B. M. K., Golztman, D., and Karaplis, A. C. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Molec Cell Biol 15:4064-4075; 1995.
14. 14. Hock, J. M., Fonseca, J., Gunness-Hey, M., Kemp, B. E., and Martin, T. J. Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. Endocrinology 125:2022-2027; 1989.
15. 15. Hock, J. M. and Gera, I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:65-72; 1992.
16. 16. Hodsman, A. B., Fraher, L. J., Ostbye, T., Adachi, J. D., and Steer, B. M. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:1138-1148; 1993.
17. 17. Johansson, A. G., Lindh, E. K., Blum, W. F., Kollerup, G. Sorensen, O. H., and Ljunghall, S. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 81:44-48; 1996.
18. 18. Karaplis, A. C., Luz, A., Glowacki, J., Bronson, R. T., Tybulewicz, V. L. J., Kronenberg, H. M., and Mulligan, R. C. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Devel 8:277-289; 1994.
19. 19. Kenny, A. M., Prestwood, K. M., Pilbeam, C. C., and Raisz, L. G. The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 80:3287-3291; 1995.
20. 20. Leaffer, D., Sweeney, M., Zvnur, Z., Vickery, B., and Caufield, J. P. PTH, PTHrP and an analog RS-66271 increase the osteoblast population of the vertebrae of ovariectomized rats after five days of dosing. J Bone Miner Res 8(suppl 1):S304; 1994.
21. 21. Lee, K., Deeds, J. D., and Segre, G. V. Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. Endocrinology 136:453-463; 1995.
22. 22. Liberman, U. A., Weiss, S. R., Broll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., Seeman, E., Recker, R. R., Capizzi, T., Santora, II, A. C., Lombardi, A., Shah, R. V., Hirsch, L. J., and Karpf, D. B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443; 1995.
23. 23. Orloff, J. J., Reddy, D. R., dePapp, A. E., Yang, K. H., Soifer, N. E., and Stewart, A. F. Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. Endocrine Rev 15:40-60; 1994.
24. 24. Pak, C. Y. C., Sakhaee, K., Adams-Huet, B., Piziak, V., Peterson, R. D., and Poindexter, J. R. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Int Med 123:401-408; 1995.
25. 25. Parisien, M., Cosman, F., Mellish, R. W. E., Schnitzer, M., Nieves, J., Silverberg, S. J., Shane, E., Kimmel, D., Recker, R. R., Bilezikian, J. P., Lindsay, R., and Dempster, D. W. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res 10:1393-1399; 1995.
26. 26. Parisien, M., Mellish, R. W. E., Silverberg, S. J., Shane, E., Lindsay, R., Bilezikian, J. P., and Dempster, D. W. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res 7:913-919; 1992.
27. 27. Parisien, M., Silverberg, S. J., Shane, E., De La Cruz, L., Lindsay, R., and Bilezikian, J. P. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 70:930-938; 1990.
28. 28. Philbrick, W. M., Wysolmerski, J. J., Galbraith, S., Holt, E., Orloff, J. J., Yang, K. H., Vasavada, R. C., Weir, E. C., Broadus, A. E., and Stewart, A. F. Defining the physiologic roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76:127-173; 1996.
29. 29. Reeve, J., Hesp, R., Williams, D., Hulme, P., Klenerman, L., Zanelli, J. M., Darby, A. J., Tregear, G. W., and Parsons, J. A. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1:1035-1038; 1976.
30. 30. Reginster, J. Y., Deroisy, R., Lecart, M. P., Sarlet, N., Zegels, B., Jupsin, I., deLongueville, M., and Franchimont, P. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 98:452-458; 1995.
31. 31. Segre, G. V. Receptors for parathyroid hormone and parathyroid hormone-related protein. Bilezikian, J. P., Levine, M. A., and Marcus, R., Eds. The parathyroids. New York: Raven; 1994;213-229.
32. 32. Silverberg, S. J., Gartenberg, F., Jacobs, T. P., Shane, E., Siris, E., Staron, R. B., and Bilezikian, J. P. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 80:723-728; 1995.
33. 33. Silverberg, S. J., Gartenberg, F., Jacobs, T. P., Shane, E., Siris, E., Staron, R. B., McMahon, D. J., and Bilezikian, J. P. Increased bone mineral density after parathyroidectomy in primary hyperparthyroidism. J Clin Endocrinol Metab 80:729-734; 1995.
34. 34. Silverberg, S. J., Shane, E., De La Cruz, L., Dempster, D. W., Feldman, F., Seldin, D., Jacobs, T. P., Siris, E. S., Cafferty, M., Parisien, M. V., Lindsay, R., Clemens, T. L., and Bilezikian, J. P. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283-291; 1989.
35. 35. Soifer, N. E., Dee, K. E., Insogna, K. L., Burtis, W. J., Matovcik, L. M., Wu, T. L., Milstone, L. M., Broadus, A. E., Philbrick, W. M., and Stewart, A. F. Parathyroid hormone-related protein: evidence for secretion of a novel mid-region fragment by three different cell types. J Biol Chem 267:236-243; 1992.
36. 36. Stewart, A. F. Humoral hypercalcemia of malignancy. Favus, M., Ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. New York: Raven; 1993;169-173.
37. 37. Stewart, A. F., Insogna, K. L., and Broadus, A. E. Malignancy-associated hypercalcemia. DeGroot, L., Ed. Endocrinology, 3rd ed. Philadelpia: Saunders; 1995; 1061-1074.
38. 38. Vickery, B. H., Zvnur, Z., Caufield, J., and Krstenansky. Studies on the bone anabolic effects in ovariectomized osteopenic rats of RS-23581, a C-terminally substituted analogue of hPTHrP(1-34). J Bone Miner Res 8(suppl 1):S200; 1994.
39. 39. Weir, E., Philbrick, W., Neff, L., Amling, M., Baron, R., and Broadus, A. Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes skeletal dysplasia and delayed osteogenesis. J Bone Miner Res 10(suppl 1):S157; 1995.
40. 40. Weir, E. C., Terwilliger, G., Sartori, L., Insogna, K. L. Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo. Calcif Tissue Int 51:30-34; 1992.
41. 41. Wilson, R. J., Rao, S., Ellis, B., Kleerekoper, M., Parfitt, M. Mild asymptomatic primary hyperparthyroidism is not a risk factor for vertebral fractures. Ann Int Med 109:959-962; 1988.